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Introduction: Enterovirus A71 (EV-A71) is an emerging 
pathogen that causes a wide range of disorders 
including severe neurological manifestations. In the 
past 20 years, this virus has been associated with 
large outbreaks of hand, foot and mouth disease 
with neurological complications in the Asia-Pacific 
region, while in Europe mainly sporadic cases have 
been reported. In spring 2016, however, an EV-A71 
outbreak associated with severe neurological cases 
was reported in Catalonia and spread further to other 
Spanish regions. Aim: Our objective was to investigate 
the epidemiology and clinical characteristics of the 
outbreak. Methods: We carried out a retrospective study 
which included 233 EV-A71-positive samples collected 
during 2016 from hospitalised patients. We analysed 
the clinical manifestations associated with EV-A71 
infections and performed phylogenetic analyses of the 
3’-VP1 and 3Dpol regions from all Spanish strains and 
a set of EV-A71 from other countries. Results: Most 
EV-A71 infections were reported in children (mean age: 
2.6 years) and the highest incidence was between May 
and July 2016 (83%). Most isolates (218/233) were 
classified as subgenogroup C1 and 217 of them were 
grouped in one cluster phylogenetically related to a 
new recombinant variant strain associated with severe 
neurological diseases in Germany and France in 2015 
and 2016. Moreover, we found a clear association of 
EV-A71-C1 infection with severe neurological disorders, 
brainstem encephalitis being the most commonly 
reported. Conclusion: An emerging recombinant 
variant of EV-A71-C1 was responsible for the large 
outbreak in 2016 in Spain that was associated with 
many severe neurological cases.
Introduction
Enterovirus 71 (EV-A71) is a small, non-enveloped, 
single-stranded RNA virus that belongs to the species 
Enterovirus A along with 24 other serotypes within 
the Enterovirus genus [1]. According to the VP1 protein 
sequence, EV-A71 is classified into six genogroups 
(A–F) and a number of subgenogroups (B0–B5, C1–C5) 
[2]. Although EV-A71 infection is often asymptomatic, 
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it can cause disorders with a wide range of clinical 
manifestations from non-specific febrile illness, 
aseptic meningitis and mild mucocutaneous symptoms 
to severe neurological diseases such as brainstem 
encephalitis and acute flaccid paralysis (AFP) [3,4].
EV-A71 is distributed worldwide. However, the largest 
outbreaks associated with hand, foot and mouth 
disease (HFMD) with subsequent neurological and 
cardiopulmonary complications have been described in 
the Asia-Pacific region, especially in the past 20 years 
[2,5-7]. These outbreaks have been connected to the 
circulation of different subgenogroups (B3, B4, C1, C2 
and C4) [8-14]. In Europe, although outbreaks of polio-
like disease occurred in Hungary and Bulgaria in the 
1970s [15,16], only sporadic cases have been reported 
from several countries in recent years, mainly caused 
by the C1 and C2 subgenogroups [2,17].
In 2015, a new recombinant EV-A71 variant was identified 
that affected at least 19 young children in different 
areas of Germany [18]. This infection was associated 
with neurological manifestations (cerebral seizures, 
myoclonia and ataxia) that required hospitalisation. 
There were no reports of fatal cases or clinical sequelae 
after hospital discharge. Moreover, a well-documented 
case, a 2-year-old girl, required hospitalisation and 
was diagnosed with brainstem encephalitis and 
cardiopulmonary complications with an outcome of 
a probable persistent neurological impairment [19]. 
In addition, 18 cases of severe neurological disease 
associated with EV-A71 infection, and phylogenetically 
closely related to the strains described in Germany, 
were reported in France between May and October 
2016. Patients presented with rhombencephalitis, 
encephalitis or encephalomyelitis, and one fatal case of 
acute cardiac failure was reported [20]. The same strain 
was also involved in a sporadic case of encephalitis in 
Poland during summer 2016 [21].
In Spain, EV-A71 was circulating at a very low rate until 
2015 [22,23]. In the spring of 2016, however, a large 
outbreak associated with severe neurological diseases 
was reported in the region of Catalonia [24-26] and 
further disseminated to the rest of the country.
In the present study, we investigated the clinical 
manifestations of EV-A71 infections and the molecular 
epidemiology and geographical spread of the strains 
detected in Spain in 2016, comparing them to strains 
circulating in Spain and other countries in recent years.
Methods
Enterovirus surveillance system
The Spanish National Reference Laboratory for 
Enterovirus (SNRLE) conducts the EV surveillance 
system at a national level. The system is voluntary 
and EV-positive clinical samples are received for 
characterisation from patients of all ages admitted 
to hospitals throughout the country. Each specimen 
Figure 1
Phylogenetic analysis of 3 -´VP1 sequences of 
enterovirus-A71, Spain, 2016 (n = 233) and representatives 
of different genogroups worldwide
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MEGA 7.0 software was used to construct the neighbour-joining and maximum 
composite likelihood tree. Bootstrap values > 70% are indicated in the branch nodes. 
CV-A16 prototype strain G-10 was used as the outgroup. Sequences are labelled with 
their GenBank accession number, country and year of isolation. Spanish sequences 
from 2016 are represented by black circles and labelled with identification number, 
country abbreviation, month and year of isolation and province.
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Figure 2
Phylogenetic analysis of 3Dpol sequences of enterovirus-A71, Spain, 2016 (n = 187) and representatives of different members 
of Enterovirus A species
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A: Alicante; AV: Ávila; B: Barcelona; EV: enterovirus; M: Madrid; MU: Murcia; Z: Zaragoza.
MEGA 7.0 software was used to construct the neighbour-joining and maximum composite likelihood tree. Bootstrap values > 70% are indicated 
in the branch nodes. EV-D68 prototype strain Fermon was used as the outgroup. Sequences are labelled with the GenBank accession number, 
country and year of isolation. Spanish sequences from 2016 are represented by black circles and labelled with country abbreviation, month 
and year of isolation and province.
4 www.eurosurveillance.org
is sent with information on patient demographics, 
clinical diagnosis and date of sample collection. For 
the purposes of this study, more detailed information 
about the severity of the symptoms, final diagnosis and 
outcome was subsequently collected from hospitals 
for patients with neurological disease. EV-positive 
samples from paediatric patients who were enrolled in 
a prospective and multicentre project (PI15CIII-0020) 
were also included in the study after informed consent 
from parents or legal guardians. This project includes 
13 representative hospitals in Spain that perform 
active surveillance of children with neurological and 
systemic diseases associated with EV and parechovirus 
infections. In addition, they provide us with extended 
clinical information about the patients. The procedure 
to collect and send samples to the SNRLE does not 
differ from the routine EV surveillance system.
Clinicians defined the severity of the neurological 
disorders according to their hospital’s protocols. 
For this study, a consensus was reached to define 
severe neurological diseases according to clinical 
manifestations; it included encephalitis (encephalitis, 
meningoencephalitis and brainstem encephalitis), AFP/
myelitis, and other motor disorders (ataxia, instability, 
cerebellitis). Mild neurological disease included 
patients with aseptic meningitis with a good evolution 
on their own.
Enterovirus characterisation and phylogenetic 
analysis
RNA was extracted from clinical samples using the 
QIAamp Viral RNA Mini Kit (QIAGEN, Germany). EV 
genotyping was performed using four specific nested 
RT-PCRs for the species EV-A, B, C and D and further 
sequencing of the 3’-VP1 region as previously described 
[27]. In EV-A71-positive samples, the 3Dpol region was 
amplified and sequenced by specific nested RT-PCR as 
previously described [28].
We carried out phylogenetic analysis based on 3’-VP1 
(359 bp) sequences of EV-71-positive samples. In 
addition, we performed 3Dpol (738 bp) analysis to 
confirm possible recombination events [28,29]. Multiple 
sequence alignments were done in the ClustalW 
programme. Genetic distances were calculated using 
the maximum composite likelihood nucleotide distance 
model, and statistical significance of phylogenies was 
estimated by bootstrap analysis with 1,000 replicates. 
Phylogenetic trees were constructed following the 
neighbour-joining method using MEGA 7.0 software. 
In the case of 3´VP1, EV-A71 sequences from 2016 
were compared with EV-A71 sequences available in 
GenBank belonging to the C1 and C2 subgenogroups 
circulating in Spain and other European countries in 
recent years, along with representative members of 
the genogroups A, B, C, D, E and F. The coxsackievirus 
(CV) A16 G-10 prototype strain (CAU05876), a member 
of Enterovirus A species, was included as an outgroup. 
For the phylogenetic analysis of 3Dpol, we compared 
EV-A71 sequences from 2016 with EV-A71 sequences 
belonging to subgenogroups C1 and C2 as well as 
sequences of members of the Enterovirus A species 
with which recombination events normally occur. The 
EV-D68 Fermon prototype strain (AY426531), a member 
of Enterovirus D species, was included as an outgroup.
The sequences obtained in this study have been 
deposited in GenBank under accession numbers 
MH394906–MH395138 (VP1 sequences) and 
MH394719–MH394905 (3Dpol sequences).
Statistical analysis
Significant variations between groups were 
evaluated using the chi-squared test. A difference 
with p value < 0.05 was considered to be statistically 
significant.
Results
Virological findings
During 2016, the SNRLE received 1,113 EV-positive 
samples (mainly CSF, serum, stools and respiratory 
samples) from 1,029 patients admitted to different 
Spanish hospitals with clinical pictures of fever without 
source (FWS) (n = 174; 16.9%), HFMD/exanthema 
(n = 52; 5.1%), respiratory illnesses (n = 270; 26.2%), 
the neurological diseases described above (n = 470; 
45.7%), and others (n = 63; 6.1%). In the case of 84 
patients from whom two different positive clinical 
samples were received, only the specimen with the 
oldest collection date was included in the study.
After discarding duplicates, 777 EV were typed, EV-A71 
being the most common serotype (n = 233; 30.0%). The 
following five most frequent serotypes were EV-D68 
(n = 148; 19.0%), echovirus (E)-30 (n = 113; 14.5%), E-5 
(n = 67; 8.6%), CV-A6 (n = 30; 3.8%) and E-7 (n = 23; 
3.0%). Three EV-A71-positive patients were co-infected 
with EV-D68, one with E-7 and one with E-11.
Epidemiological data of patients with 
enterovirus A71
Specimens of EV-A71 were isolated mainly from 
respiratory (n = 150, 64.4%) and stool samples (n = 71, 
30.5%) but were also detected in cerebrospinal fluid 
(n = 8, 3.4%) and serum (n = 4, 1.7%). Both a respiratory 
and a stool sample were available in 34 EV-A71 cases. 
EV-A71 was only successfully genotyped from both 
samples in 15 of these cases. Patients’ ages ranged 
from 1 day to 63 years, with a mean of 2.6 years (n = 231 
with available information on age; standard deviation 
(SD) = 5.35; median = 1.86; 95th percentile = 5.9). The 
male/female sex ratio was 1.5/1. The period from 
symptom onset to collection date was only provided in 
36 cases with a mean of 3.3 days (SD = 1.9; median = 3).
Phylogenetic analysis of enterovirus-A71
The VP1 phylogenetic analysis revealed that most 
of the Spanish sequences from 2016 (218/233) 
belonged to subgenogroup C1. Of these, 217 formed 
a separate group within the C1 cluster together with 
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sequences from a new recombinant variant described 
in Germany in 2015 (bootstrap value > 95%) (Figure 1, 
Supplementary Figure S1) [18], while one C1 isolate 
grouped with EV-A71-C1 sequences from previous 
years. The remaining 15 sequences were grouped 
within the subgenogroup C2 cluster.
Because of insufficient sample volume or unsuccessful 
sequencing, only 187 sequences were available for 
the 3Dpol phylogenetic analysis. Similarly to the VP1 
analysis, most sequences appeared in one differentiated 
cluster which again included the sequences from 
Germany in 2015 (bootstrap value > 76%) (Figure 2, 
Supplementary Figure S2). Interestingly, the same 
sequences that were grouped in the C2 subgenogroup 
cluster according to the VP1 sequence, were also 
grouped separately in an interspersed cluster together 
with C1 and C2 subgenogroups sequences.
Temporal and geographical distribution of 
enterovirus-A71
The total of 233 EV-A71-positive samples were collected 
from 45 different hospitals in 26 of the 50 Spanish 
provinces and from Andorra. Barcelona and Madrid, 
the most populated provinces in Spain, were the two 
with the highest number of cases (Figure 3). The first 
cases of the outbreak (subgenogroup C1-variant) 
were described in Catalonia in April 2016. From May 
onwards, the number of cases increased, most of them 
concentrated between May and July (Figure 4), and 
spread throughout the country. The last two cases 
were reported in December. A sporadic case associated 
to subgenogroup C1 but unrelated to the outbreak was 
reported in February 2016. The cases associated with 
the subgenogroup C2 were distributed from April to 
July (Figure 4).
Clinical presentations of enterovirus-A71 
infections
Patients involved in the outbreak (EV-A71-C1-variant; 
n = 217) were diagnosed with HFMD or herpangina 
(n = 8; 3.7%), FWS (n = 14; 6.5%), lower respiratory 
tract infection (n = 17; 7.8%), neurological symptoms 
(n = 167; 77.0%) and other symptoms (n = 11; 5.1%) 
(Table). There was a significantly higher proportion 
of neurological manifestations with EV-A71-C1-variant 
infection with severe symptomatology (n = 140; 64.5%) 
compared with those with mild symptomatology 
(n = 27; 12.4%) (p < 0.0001) (Table). Among the patients 
infected with EV-A71-C2, five had mild neurological 
disease, five had severe neurological disease, three 
had lower respiratory tract infection and two had FWS. 
Figure 3
Geographical distribution of enterovirus-A71 cases, Spain, 2016 (n = 233)
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The remaining non-outbreak-related EV-A71-C1 case 
was reported as having FWS (Table).
According to the data provided by hospitals, 22.9% 
(33/144) of the children with severe neurological 
diseases required admission to a paediatric intensive 
care unit and 65.3% of them (94/144) received some 
treatment (intravenous gamma globulin or/and 
corticoids). After 90 days of follow-up, 88.2% (n = 127) 
of them had no significant sequelae.
To confirm the association of EV-A71-C1-variant 
infection with severity, we analysed the total of severe 
neurological infections positive for EV during 2016 
(n = 190). Meningoencephalitis was the most common 
clinical manifestation (n = 79; 41.6%) followed by 
brainstem encephalitis (n = 58; 30.5%), encephalitis 
(n = 26; 13.7%), AFP/myelitis (n = 17; 8.9%) and other 
motor disorders (n = 10; 5.3%). EV-A71-C1-variant was 
responsible for most cases (n = 140; 73.7%) compared 
with EV-A71-C2 (n = 5, 2.6%) and other EV types that 
included EV-D68, E-30, CV-B3, E-5, E-7, CV-A6, E-18, 
CV-A10, CV-A4, CV-B1, E-20, E-6 and E-9 (n = 45, 23.7%) 
(p < 0.001).
Discussion
This study presents the clinical and virological 
characterisation of the EV-A71 strains reported in 
Spain in 2016. We identified EV-A71 subgenogroup 
C1 as responsible for a large outbreak that affected 
young children throughout Spain in 2016 and the clear 
association of this infection with severe neurological 
diseases.
Since the outbreaks of polio-like disease in Bulgaria 
and Hungary in 1975 and 1978 [15,16], the number of 
EV-A71-associated neurological diseases has been low 
in Europe compared with the Asia-Pacific region, and 
most documented EV-A71 infections included sporadic 
cases of febrile illness, HFMD and meningitis [5,6]. 
However, several cases of EV-A71 infections associated 
with severe neurological disorders in children were 
reported in Germany and France during 2015 and 2016 
[18-20]. In Spain, an increasing number of EV-A71 
infections was noticed in 2016 compared with previous 
years. From 2000 to 2015, the SNLRE had identified 
an average of two isolates of EV-A71 per year with a 
maximum of seven cases in 2012 [22,23,30].
Regarding specimen types, EV-A71 was mainly detected 
in either respiratory samples or stools (or both). This is 
in agreement with several studies that claim that EVs 
are isolated from CSF only in a minority of patients, 
whereas recovery from peripheral sites such as throat, 
stool/rectum and vesicle fluid is more common [3,29]. 
This finding suggests that in severe neurological 
disease, respiratory and stool specimens, in addition 
to the CSF and serum samples, should be submitted 
for EV testing.
According to the 3´-VP1 sequence, most EV-A71 
sequences in Spain during 2016 (217/233) showed 
a high similarity with the German strains reported 
in 2015 and were classified as subgenogroup C1. 
The fact that according to the 3Dpol sequence our 
strains also grouped together with the German strains 
indicates that it is very probably the same recombinant 
variant, although whole genome sequencing would be 
necessary to confirm this hypothesis.
We found an association between infection with this 
recombinant variant and the severity of the neurological 
manifestations, consistent with the German and 
Figure 4
Temporal distribution of enterovirus-A71 cases, by epidemiological week, Spain, 2016 (n = 233)
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French reports [18-20]. In addition, most patients did 
not present HFMD before developing neurological 
manifestations (Table), also in agreement with the 
German and French reports but not with the numerous 
publications from outbreaks in Asia-Pacific in recent 
years [31-34]. Several clinical features such as young age 
or fever have been associated with severe neurological 
EV-A71 disease [3]. On the other hand, the absence 
of mucocutaneous ulcers that we saw in patients in 
our study has not been related to the development 
of complicated or fatal cases by other studies [3]. 
Interestingly, most of the 15 EV-A71-C2 cases and the 
one EV-A71-C1 case unrelated to the outbreak were not 
associated with severe neurological disease. Since no 
particular genogroup has been conclusively associated 
with greater virulence or certain clinical manifestations 
[5,35] and taking into account that in most cases, host 
factors play a determining role in the development of 
the disease, further experiments would need to be 
performed in order to describe the viral determinants 
responsible for this new recombinant strain being 
associated with severe neurological pathology.
The reason why the same recombinant variant caused 
such a large outbreak in Spain, while only a limited 
number of cases were reported in Germany and 
France, remains unknown. Large epidemics have been 
associated with genogroup replacement [5,36,37]. 
This would be in agreement with the low circulation 
of subgenogroup C1 in Spain before 2016 [22,23,30] 
in contrast to the situation in Germany and France 
[2,17,38,39]. Low seroprevalence against EV-A71 in a 
specific area may facilitate the emergence of a strain 
that causes an outbreak, especially in young children 
[40]. However, as non-polio EV infection is not a 
notifiable disease in Spain and asymptomatic strains 
may have been circulating during recent years, the real 
number of EV-A71 infections could be underestimated. 
Unfortunately, no seroprevalence studies are available 
in Spain to confirm this hypothesis. It is important 
to highlight that we have identified sporadic cases 
associated with this EV-A71-C1 variant in 2017 and 
2018 (data not shown), indicating that this variant is 
still circulating in Spain, but with lower incidence. The 
seasonality of the cases during 2016, including C1 and 
C2 subgenogroups, was similar to previously described 
epidemics of EV in Spain [22,23,30]. Moreover, the 
geographical distribution of the outbreak indicates 
that it was not restricted to the region of Catalonia, but 
distributed throughout Spain.
As more severe neurological cases occurred during this 
outbreak, there was concern among the population, 
the media and health professionals. Because of 
this concern, there was constant communication 
among microbiologists, epidemiologists and clinical 
paediatricians at national level, in which the National 
Centre for Microbiology was involved. For this reason, 
we strongly believe that we studied a large and 
representative number of cases although we have the 
limitation of not being able to know with certainty the 
final number of cases of the outbreak. In addition, it 
should be noted that we were informed that most severe 
cases were diagnosed virologically, and only some 
Table
Clinical manifestations among enterovirus-A71 patients, Spain, 2016 (n = 233)
Number of cases % p value HFMD-associated
Patients infected with EV-A71-C1 variant (n = 217)
Neurological disorders
Severe
Brain stem encephalitis 53
64.5 Not applicable
4
Meningoencephalitis 47
Encephalitis 18 1
AFP/myelitis 12
Other motor disorders 10 3
Mild
Aseptic meningitis 25
12.4 < 0.001
4
Other 2
Lower respiratory tract infection 17 7.8 < 0.001
Mucocutaneous symptoms 8 3.7 < 0.001
Fever without source 14 6.5 < 0.001
Other 11 5.0 < 0.001
Patients infected with EV-A71-C1 or C2 (n = 16)
Neurological disorders
Severe
Brain stem encephalitis 2
31.2 Not applicable
Meningoencephalitis 3
Mild Aseptic meningitis 5 31.2 0.069 1
Lower respiratory tract infection 3 18.8 0.195
Fever without source 3 18.8 0.195  
AFP: acute flaccid paralysis; EV: enterovirus; HFMD: hand, foot and mouth disease.
Significant variations between groups were evaluated by chi-squared test; p values comparing the number of cases with severe neurological 
disorders with the remaining clinical manifestations are shown.
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mild cases were missed [41]. On the other hand, since 
the Spanish surveillance system is voluntary, there is a 
risk of having a bias because hospitals are more likely 
to send samples of severe patients. As mentioned 
above, 777 EV-positive samples were genotyped at the 
SNLRE during 2016. Of those, only 190 (25%) belonged 
to patients with severe neurological disorders. The fact 
that most samples received in the laboratory during 
2016 were from patients with mild symptoms, as well 
as in previous years, minimises this risk.
Another limitation of our study could be that hospitals 
may have a bias towards reporting cases in children. 
Since EV infections are clearly associated with chil-
dren, it seems that this is a bias than cannot be pre-
vented; however, samples from patients of all ages 
were received in 2016. Our laboratory has previously 
described the association of some serotypes with dif-
ferent age groups [23]. Our results suggest an asso-
ciation of infection with EV-A71-C1 variant in young 
children.
Finally, more Spanish regions could have been affected 
for which we may not have had data, either because 
some hospitals did not send samples or because some 
samples received from reference hospitals, mostly in 
Barcelona and Madrid, belonged to patients admitted 
from the surrounding regions. For the purposes of this 
study, we selected the affected regions according to 
the hospitals that sent the clinical samples. This is 
the reason why, for instance, Barcelona is the only 
province of the region of Catalonia in which the cases 
were reported.
Conclusion
In summary, our results show that an emerging 
EV-A71-C1 strain was responsible for the outbreak in 
Spain during 2016 and was associated with many severe 
neurological cases, the largest outbreak in Europe in 
recent years. This is the first time that this EV-A71-C1 
variant has been detected in Spain and it could have 
its origin in strains from other European countries such 
as Germany or France. Since poliovirus eradication is 
a reasonable goal in the short term, surveillance of 
non-polio EV associated with neurological implications 
becomes crucial, especially in cases such as EV-A71 
infection where no treatments or vaccines are available. 
In this sense, the recently established European 
Non-Polio-Enterovirus Network [29] can contribute to 
standardising methods for EV detection and typing, 
clarifying the most adequate specimens for testing 
according to the clinical presentation and, ultimately, 
monitoring the global circulation of EV types. Our 
findings highlight the importance of EV surveillance 
in order to identify new recombinant forms of known 
EV types and monitor their associated disease burden, 
their molecular epidemiology and geographical 
distribution.
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